Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Neovascular AMD patients who are eligible for Macugen therapy based on the approved label

Exclusion Criteria:

• Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.